RASSF2 and benign prostatic hyperplasia: Aykanli et al. (2024) [28] evaluated a three DMG panel (qMSP; GSTP1, RASSF1, and RASSF2) in the blood (PCa n = 13; high-grade intraepithelial neoplasia n = 3; BPH n = 20; atypical small acinar proliferation n = 3; HD n = 15).